VIRTUAL MEETING – Insights into Medicine Developability: Formulation, Toxicology and Clinical Studies
November 6 @ 09:30 - 13:00| £10.00 – £100.00
This virtual APS meeting in collaboration with the Centre for Doctoral Training in Transformative Pharmaceutical Technologies, (University of Nottingham, University College London and Synthesis and Solid State Pharmaceutical Centre, University of Limerick) aims to provide an insight into the development of new medicines with information provided on the formulation, toxicology and clinical studies required to progress a new molecule to early clinical studies.
The presentations are given by leading practitioners from major companies.
It is ideally suited to students studying the pharmaceutical sciences or related subjects and to those in academia or industry wishing to improve or broaden their knowledge of drug development.
Friday 6th November 2020
9.30-9.35-Welcome: Prof Maria Marlow (University of Nottingham) & Dr John Wahlich (APS Advisory Board).
Introduce Mei Wong-Senior Principal Scientist within the Drug Product Design group at Pfizer.
9.35-10.35- Mei Wong-Early Clinical Formulations
Introduce Paul Giffen-Senior Project Toxicologist, GSK
10.45-11.45-Paul Griffen-Non-Clinical Drug Development: Toxicology Studies
Introduce Peter Scholes-Chief Scientific Officer at Quotient Sciences
11.55-12.55-Peter Scholes-Designing and delivering an early development clinical programme
12.55-Closing remarks- Prof Maria Marlow (University of Nottingham) & Dr John Wahlich (APS Advisory Board)
Dr John Wahlich-Chair
John has been a consultant in the pharmaceutical sciences for over 6 years. Prior to that he had over 40 years’ experience in product development in the pharmaceutical industry. John is a chemist by training (PhD from Nottingham School of Pharmacy) and has analytical and formulation expertise gained from leadership roles in product line extensions, physical properties and early stage development in GlaxoSmithKline and other major pharmaceutical companies. He is a former vice president of the APS and is now a member of the APS Advisory Board.
Paul is a Senior Project Toxicologist within the AstraZeneca’s Regulatory Safety group in Cambridge where his primary role is to oversee the non-clinical development of respiratory based products. Paul has worked in the pharmaceutical industry for over 27 years (GSK and AZ) with the majority of that time within Safety Assessment where he has also held roles of Clinical Pathologist and Study Director. Paul has oversight in the design and conduct of appropriate regulatory toxicology packages to support internal and external asset development in accordance with appropriate guidelines. In addition to the development of pharmaceutical ingredients, Paul also gained experience in the development and safety evaluation of novel dry powder inhalation platforms.
For a 3 year period, Paul worked within the Drug Delivery group (GSK) to support the identification, evaluation and development (CMC and safety) of novel drug delivery platforms (for example long acting injections and Microneedles) to meet portfolio needs and to improve parameters such as patient compliance, delivery efficiency and reduced toxicity.
Mei is a Senior Principal Scientist within the Drug Product Design group at Pfizer. She has over 10 years of formulation development experience across all the different stages of drug product development, from pre-clinical to commercialisation. She is a pharmacist by training and has a Pharmaceutics PhD from the School of Pharmacy, University of London.
Peter read Pharmaceutical Sciences at the University of Nottingham, UK, gaining his PhD in 1993. He has over 25 years’ experience in the Pharmaceutical Industry and joined Quotient Sciences in 2007. Peter has been instrumental in developing innovative and adaptive approaches to integrate pharmaceutical development and clinical testing in early research. He was appointed to the position of CSO in March 2013 where he now has responsibility for the scientific strategy and leadership at Quotient. Peter has previously served as a committee member for the UK Controlled Release Society and APS Biopharmaceutics focus group and in 2013 set up a GastroPlus user group with industry colleagues as a discussion forum for PBPK modelling and simulation science. In 2010, Peter was named one of PharmaVOICE’s 100 most inspiring people in the life-sciences industry. He was appointed as an Honorary Professor in Pharmaceutical Sciences at Nottingham University in August 2015.